Can-Fite BioPharma Ltd.
CANF · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $674 | $743 | $810 | $853 |
| % Growth | -9.3% | -8.3% | -5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $674 | $743 | $810 | $853 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $5,757 | $5,983 | $7,763 | $9,850 |
| G&A Expenses | $3,047 | $2,955 | $3,143 | $3,845 |
| SG&A Expenses | $3,047 | $2,955 | $3,143 | $3,845 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8,804 | $8,938 | $10,906 | $13,695 |
| Operating Income | -$8,130 | -$8,195 | -$10,096 | -$12,842 |
| % Margin | -1,206.2% | -1,103% | -1,246.4% | -1,505.5% |
| Other Income/Exp. Net | $250 | $561 | -$77 | $227 |
| Pre-Tax Income | -$7,880 | -$7,634 | -$10,173 | -$12,615 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,880 | -$7,634 | -$10,173 | -$12,595 |
| % Margin | -1,169.1% | -1,027.5% | -1,255.9% | -1,476.6% |
| EPS | -1.08 | -1.8 | -3.75 | -9 |
| % Growth | 40% | 52% | 58.3% | – |
| EPS Diluted | -1.08 | -1.8 | -3.75 | -8.25 |
| Weighted Avg Shares Out | 7,254 | 4,262 | 2,719 | 1,530 |
| Weighted Avg Shares Out Dil | 7,253 | 4,261 | 2,719 | 1,844 |
| Supplemental Information | – | – | – | – |
| Interest Income | $291 | $506 | $222 | $24 |
| Interest Expense | $14 | $14 | $16 | $18 |
| Depreciation & Amortization | $7 | $15 | $14 | $14 |
| EBITDA | -$8,123 | -$8,180 | -$10,082 | -$12,828 |
| % Margin | -1,205.2% | -1,100.9% | -1,244.7% | -1,503.9% |